Forteo no better than oral risedronate for back pain from vertebral fractures
This article was originally published in Scrip
Eli Lilly reported that its bone-building anabolic drug Forteo (teriparatide [rDNA origin] injection) was no more effective than oral risedronate (Warner Chilcott's Actonel) in a Phase III clinical trial evaluating the relief of back pain for women with osteoporotic vertebral fractures.
You may also be interested in...
Public Company Edition: Also, Teva sells $2.1bn in notes to pay prior debts. In restructurings, Baudax splits off from Recro, while three firms shift their focus to specific cell therapy programs.
The company and partner Vifor said the selective complement 5a receptor inhibitor met both primary and multiple secondary endpoints; US and EU filings are planned for 2020.